title: Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
abstract: The presence of high numbers of somatostatin receptors seems to be the basis for the successful control by Sandostatin of hormonal hypersecretion by most growth hormone-secreting pituitary adenomas, endocrine pancreatic tumors, and carcinoids. In this report, we present preliminary data on in vivo somatostatin receptor imaging with a 123I-coupled somatostatin analog (204-090) in patients with these types of tumors.
authors.affiliation: Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
authors.forename: S W
authors.initials: SW
authors.lastname: Lamberts
authors.forename: W H
authors.initials: WH
authors.lastname: Bakker
authors.forename: J C
authors.initials: JC
authors.lastname: Reubi
authors.forename: E P
authors.initials: EP
authors.lastname: Krenning
mesh_terms: D002276:Carcinoid Tumor / Q000000981:diagnostic imaging*; D006801:Humans; D007457:Iodine Radioisotopes; D015282:Octreotide / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D009384:Paraneoplastic Endocrine Syndromes / Q000000981:diagnostic imaging*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D011877:Radionuclide Imaging; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D017481:Receptors, Somatostatin
chemical_list: D007457:Iodine Radioisotopes; D017981:Receptors, Neurotransmitter; D017481:Receptors, Somatostatin; C045210:3-Tyr-octreotide; D015282:Octreotide